Circassia closes $98 million fundraising for lead allergy programmes Circassia Ltd.

‘We’ve achieved positive phase II results inside our three lead allergy programmes and extended our portfolio in to the autoimmunity field. Since Circassia‘s establishment five years ago, we’ve built a ongoing firm with a wide pipeline, completed numerous phase II trials and elevated significant investment funding. The new funding announced today will allow us to build upon this progress, and transform Circassia right into a world-course immunotherapy business.’ Susan Searle, Chief Executive Officer of Imperial Innovations, stated, ‘We’ve led each investment circular for Circassia because the company was founded, and so are delighted to do so again. Circassia has produced great progress in the last five years, and we are very happy to contribute to this following transformational stage in the company’s growth.’..On the standard metric of life span at birth, Britain outscores America . However, Britain scores even worse than America in five-year survival prices for cancer.’ ‘Both wellness systems possess their virtues and their faults. At its greatest, America offers extraordinarily good clinical care, but too many people lack insurance cover or fret about dropping it. The NHS provides healthcare to all or any at a lower total cost, but patients have much less clout. Both countries are crying out for reforms to bring about better and cheaper care’ .